Antimicrobial Peptides Display Strong Synergy with Vancomycin Against Vancomycin-Resistant E. faecium, S. aureus, and Wild-Type E. coli

Int J Mol Sci. 2020 Jun 27;21(13):4578. doi: 10.3390/ijms21134578.

Abstract

There is an urgent and imminent need to develop new antimicrobials to fight against antibiotic-resistant bacterial and fungal strains. In this study, a checkerboard method was used to evaluate the synergistic effects of the antimicrobial peptide P-113 and its bulky non-nature amino acid substituted derivatives with vancomycin against vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and wild-type Escherichia coli. Boron-dipyrro-methene (BODIPY) labeled vancomycin was used to characterize the interactions between the peptides, vancomycin, and bacterial strains. Moreover, neutralization of antibiotic-induced releasing of lipopolysaccharide (LPS) from E. coli by the peptides was obtained. Among these peptides, Bip-P-113 demonstrated the best minimal inhibitory concentrations (MICs), antibiotics synergism, bacterial membrane permeabilization, and supernatant LPS neutralizing activities against the bacteria studied. These results could help in developing antimicrobial peptides that have synergistic activity with large size glycopeptides such as vancomycin in therapeutic applications.

Keywords: antibiotic resistance; antimicrobial peptide; bulky non-nature amino acid; synergism; vancomycin.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Drug Synergism*
  • Enterococcus faecium / drug effects*
  • Escherichia coli / drug effects*
  • Microbial Sensitivity Tests
  • Pore Forming Cytotoxic Proteins / pharmacology*
  • Staphylococcus aureus / drug effects*
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Pore Forming Cytotoxic Proteins
  • Vancomycin